

TETRAVANADATE IS AN INHIBITOR OF PHOSPHATIDYL INOSITOL-SPECIFIC PHOSPHOLIPASE C


A. Stewart Campbell & Gregory R.J. Thatcher*

Department of Chemistry, Queen's University,
 Kingston, Ontario, K7L 3N6, Canada

(Received 24 March 1992)

Abstract: Monitoring of oligomer concentrations by ^{51}V nmr demonstrates the tetramer of vanadate ion to be a potent inhibitor of phosphatidyl inositol specific phospholipase C (PI-PLC) from *Bacillus Cereus*.

Within the last few years there has been an explosion of research in the area of inositol phosphates (IP's) and phosphatidylinositols (PI's), stimulated by discoveries of their roles as intracellular messengers¹ and membrane anchors for proteins and oligosaccharides². The key enzyme involved in these biological pathways is PI-PLC, which is responsible for direct generation of the important second messenger inositol-1,4,5,-trisphosphate (IP_3) from phosphatidylinositol-4,5-bisphosphate (PIP_2) (Scheme 1a)^{1,3}. In addition, it has become apparent that inositol cyclic phosphates (cIP's) may also be released as direct products of PI-PLC action^{1b,4}. In some cases these cIP's are the sole inositol-containing product⁵. The action of PI-PLC on PI-linked membrane-bound glycoproteins and oligosaccharides (Scheme 1b) is anticipated to generate cIP's². Indeed we have shown that action of PI-PLC from *B.Cereus* on PI yields inositol cyclic



-1,2-phosphate (cIP) as product⁶. In this work we define the tetramer of vanadate as an inhibitor of this activity⁹. The potential for inhibition of PI-PLC by tetravanadate must be recognized, in particular in light of recent reports on the effects of decavanadate^{10a} and orthovanadate^{10b} on IP and PI-dependent processes¹¹.

It has been proposed that: (1) vanadates may form stable pentacoordinate trigonal bipyramidal species in solution¹² and at the active site of phosphoryl transfer enzymes such as ribonuclease¹³, and; (2) spontaneous esterification is undergone by vanadate in aqueous solution in the presence of a variety of alcohols, including glycols and sugars¹⁴. Thus, the potential for an inositol:vanadate complex to bind at the active site and inhibit PI-PLC was examined. Initial observations of PI-PLC inhibition by vanadate did not define the inhibitor species⁷. Vanadates and their esters are known to spontaneously oligomerise in solution, the relative amounts being pH and concentration dependent¹⁵. Previously, oligomeric vanadate species, such as decavanadate^{10a} and tetravanadate¹⁶, have been shown to be potentially potent inhibitors of biological processes. This work represents the first report of inhibition of a phosphodiesterase by tetravanadate¹⁷.




Figure 1a. ^{51}V nmr spectra of PI-PLC reaction solutions at indicated total vanadium concentration: SF=105.25MHz; SI=8k; SW=25KHz; PW=12us; LB=20Hz; RD=.34s; referenced to pH7.5 solution containing vanadate-ethanolamine complex ($\delta_v = -488\text{ppm}$ relative to VOCl_3 external reference at 0ppm). Key: M=monomer; D=dimer; T=tetramer; O=higher oligomer. **Figure 1b.** PI-PLC enzyme assay data. Reactions monitored by ^{31}P nmr from ratio of PI and cIP integrated signals. Conditions: 50mM HEPES (pH 7.31 with NaOH); .19% Triton X-100. Pre-incubation for 1hr prior to addition of PI (8.2mg, Avanti) solution, PI-PLC (1.3mU/ml, Boehringer) used as supplied.

Reactions were followed by ^{31}P nmr and vanadium species were identified by ^{51}V nmr. At 6.2mM total vanadium concentration ($[\text{V}]_t$) in HEPES buffer at pH 7.3 with and without inositol, the inhibition plot and ^{51}V spectra are virtually indistinguishable. Causes for the absence of a signal due to an inositol/vanadate complex must be considered. Firstly, signal overlap has been observed in cases where there is rapid ligand exchange with vanadate and the signals therefore coalesce¹⁸. This is doubtful for a 1:1 complex involving a

cyclic diester, since the vanadium in this case should be pentacoordinate¹⁹, showing the typical ^{51}V nmr signal downfield from vanadate (-520 ppm). No signal was observed in this region. The presence of a 1:1 monoester cannot be ruled out on these grounds, because signal coalescence is possible, and has indeed been quantified in other cases¹⁸. In general, a high concentration of alcohol is found to be required for observation of complex formation^{12,13c}. In the case of ribonuclease, the inhibitor, a 1:1 uridine:vanadate complex, was undetectable by ^{51}V nmr, although a 2:2 dimer complex was observed²⁰. In our case at $[\text{V}]_t = [\text{inositol}] = 6.2\text{mM}$, too little complex is present to be detectable by ^{51}V nmr: at 100mM inositol no complex is observed; at 0.6M inositol ($[\text{V}]_t = 3\text{mM}$; pH 7.5) appropriate ^{51}V signals are detected, including major signals at $\delta = -501, -514$ ppm. The evidence does not rule out the existence of inositol:vanadate complexes at low $[\text{V}]_t$, but clearly such a complex is not required for inhibition of PI-PLC by vanadate.

The ^{51}V nmr spectrum illustrates that, at 6.2mM in the enzyme assay medium, vanadate is present almost exclusively in tetrameric form, in agreement with previously reported spectra^{14,16a}. This led to a series of studies using total vanadium concentrations ranging from 0.50 - 4.00 mM. The degree of inhibition was analysed in parallel to the ^{51}V spectrum of each PI-PLC solution. At lower $[\text{V}]_t$, the dominant species in solution is the monomer^{15b,16a}, and almost no tetramer exists (Fig. 1a). There is little inhibition of PI-PLC activity by vanadate at these levels (Fig. 1b). However, the amount of tetramer begins to rise sharply near 2.00 mM $[\text{V}]_t$ (Fig. 1b). A corresponding increase in enzyme inhibition indicates that tetravanadate may be the inhibitory species.




Figure 2. Dixon-type plot showing correlation of inhibition with concentration of each vanadate species. Inverse rate data obtained at 10% reaction. Linear regression for dimer and monomer yield $R^2 = 0.86$ and 0.25 respectively. Correlations at 5% and 15% reaction yield identical results.

Due to potential error in integration of ^{51}V nmr spectra¹⁵ and the kinetic data (followed by ^{31}P nmr), it would be dangerous to extract detailed rate and inhibition constants from these data²¹. The observed scatter (Fig. 2) clearly demonstrates that inhibition does not correlate with concentration of monomer. Only inhibition with respect to tetravanadate yields a linear relationship. Molecular mechanics calculations and comparison with crystal structure data²² suggest tetravanadate to be approximately isosteric and isoelectronic with cIP ,²³. Specific vanadate-protein interactions are as yet unmapped, although interaction with lysine and arginine residues is to be expected^{16d,24}. Detailed inhibition studies are in progress to define the mechanism of inhibition. The present study demonstrates that tetravanadate does inhibit the PI pathway

at the PI-PLC level, with the corollary that significant total vanadate concentrations ($>2\text{mM}$) are required to observe potent inhibition²⁵.

References

1. For example: (a) Berridge, M.J. and Irvine, R.F., *Nature* 1989, **341**, 197-205; (b) Majerus, P.W., Ross, T.S., Cunningham, T.W., Caldwell, K.K., Jefferson, A.B., Bansal, V.S., *Cell* 1990, **63**, 459-465.
2. (a) Low, M.G. and Saltiel, A.R., *Science* 1988, **239**, 268-275; (b) Czech, M.P., Klarlund, J.K., Yagaloff, K.A., Bradford, A.P., Lewis, R.F., *J. Biol. Chem.* 1988, **263**, 11017-11020.
3. Rhee, S.G., Suh, P.-G., Ryu, S.-H., Lee, S.Y., *Science* 1989, **244**, 546-550.
4. (a) Wilson, D.B., Connolly, T.M., Bross, T.E., Majerus, P.W., Sherman, W.R., Tyler, A.N., Rubin, L.J., Brown, J.E., *J. Biol. Chem.* 1985, **260**, 13496-13501; (b) Connolly, T.M., Wilson, D.B., Bross, T.E., Majerus, P.W., *J. Biol. Chem.* 1986, **261**, 122-126; (c) Sekar, M.C., Dixon, J.F., Hokin, L.E., *J. Biol. Chem.* 1987, **262**, 340-344.
5. (a) Ikezawa, H. and Taguchi, R., *Meth. Enzymol.* 1981, **71**, 731-741; (b) Volwerk, J.J., Shashidhar, M.S., Kuppe, A., Griffith, O.H., *Biochem.* 1990, **29**, 8056-8062.
6. No conversion from cIP to I-1-P was observed under normal assay conditions. Only when the PI-PLC concentration was increased by 100-fold was there observed hydrolysis of cIP, albeit at an extremely slow rate⁷. This observation is in complete accord with ref. 8.
7. Campbell, A.S. and Thatcher, G.R.J., *Tetrahed. Lett.* 1991, 2207-2210.
8. Lin, G., Bennet, C.F., Tsai, M.-D., *Biochem.* 1990, **29**, 2747-2757.
9. First presented at the 74th Canadian Chemical Conference and Exhibition 1991, Abstr. No. 106.
10. (a) Fohr, K.J., Wahl, Y., Engling, R., Kemmer, T.P., Gratzl, M., *Cell Calcium* 1991, **12**, 735-742; (b) Randazzo, P.A., Olshan, J.S., Bijlvi, A.A., Jarett, L., *Arch. Biochem. Biophys.* 1992, **292**, 258-265; (c) Heyliger C.E., Tahiliani A.G., McNeil J.H., *Science*, 1985, **227**, 1474-77.
11. Decavanadate is shown to be an IP₃ antagonist at the IP₃ receptor^{10a}. Orthovanadate stimulates PI-PLC activity^{10b}. Both vanadate and GlcP have been shown to elicit insulinomimetic activity^{2b,10c}. The interaction of tetravanadate with PI-PLC reported in this paper may either potentiate or counteract these other biological effects of vanadate ion and must be taken into account.
12. Gresser, M.J. and Tracey, A.S., *J. Amer. Chem. Soc.* 1986, **108**, 1935-1939.
13. (a) Wlodawer, A., Miller, M., Sjolín, L., *Proc. Nat. Acad. Sci. USA* 1983, **80**, 3628-3631; (b) Borah, B., Chen, C.-W., Egan, W., Miller, M., Wlodawer, A., Cohen, J.J., *Biochem.* 1985, **24**, 2058-2067; (c) Lindquist, R.N., Lynn, J.L.Jr., Lienhard, G.E., *J. Amer. Chem. Soc.* 1973, **95**, 8762-8768.
14. Tracey, A.S. and Gresser, M.J., *Can. J. Chem.* 1988, **66**, 2570-2574.
15. (a) Rehder, D., *Angew. Chem. Int. Ed. Engl.* 1991, **30**, 148-167; (b) Pope, M.T., *Heteropoly and Isopoly-oxometalates*. Springer-Verlag, New York, 1983.
16. (a) Crans, D.C., Willging, E.M., Butler, S.R., *J. Amer. Chem. Soc.* 1990, **112**, 427-432; (b) Crans D.C. & Schelbe S.M., *Biochem.* 1990, **29**, 6698-6706; (c) Crans D.C. & Simone C.M., *Biochem.* 1991, **30**, 6734-41; (d) Wittenkeller L., Abraha A., Ramasamy R., de Freitas D.M., Theisen L.A., Crans D.C., *J. Amer. Chem. Soc.* 1991, **113**, 7872-81.
17. Tetravanadate has been reported as an enzyme inhibitor competitive with substrate and/or cofactor¹⁶, but not previously in the case of phosphatase and phosphotransferase enzymes.
18. Tracey, A.S., Gresser, M.J., Galeffi, B., *Inorg. Chem.* 1988, **27**, 157-161.
19. Tracey, A.S. and Gresser, M.J., *Inorg. Chem.* 1988, **27**, 2695-2702.
20. Tracey, A.S., Gresser, M.J., Liu, S., *J. Amer. Chem. Soc.* 1988, **110**, 5869-5874.
21. The x-intercept (Fig.2) gives an approximate maximal value for K_i of 96 μM : a figure comparable to values of K_i previously reported for tetravanadate¹⁶.
22. Fuchs, J., Mahjour, S., Pickardt, J., *Angew. Cem. Int. Ed. Engl.* 1976, **15**, 374-375; Day V.W., Klemperer W.G. & Yagasaki A., *Chem. Lett.* 1990, 1267-70.
23. The lack of rigorous parameterization for cyclic phosphate and vanadate in MM calculations and the structural variation in tetravanadate crystal structures must be recognized.
24. Jaswal, J.S. and Tracey, A.S., *Can. J. Chem.* 1991, **69**, 1600-1607.
25. NSERC(Canada) and Queen's University ARC are thanked for financial support.